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Abstract
Background: Reticulocyte-type 15-lipoxygenase-1
(ALOX15) has anti-inflammatory and inflammatory
effects and is implicated in the development of asth-
ma, arthritis and atherosclerosis. Previously, we
screened the human ALOX15 gene for variations
because genetic variability in ALOX15 might influence
these diseases. We found a C)T substitution at posi-
tion c.–292 in the ALOX15 promoter that created a
novel binding site for the transcription factor SPI1 and
increased ALOX15 mRNA levels in monocytes from
c.–292CT heterozygous volunteers.
Methods: To test whether the higher mRNA levels led
to higher ALOX15 activity, we performed an activity
assay and measured the arachidonic acid metabolite
15(S)-hydroxy-eicosatetraenoic acid w15(S)-HETEx by
HPLC analysis. To test whether this polymorphism
was associated with coronary artery disease (CAD),
we investigated its association in a case-control study
involving 498 Caucasians.
Results: The c.–292C)T polymorphism was associ-
ated with higher enzyme activity in heterozygous car-
riers. Intriguingly, this polymorphism also showed a
tendency to be protective against atherosclerosis.
Conclusions: These results suggest that increased
ALOX15 activity may attenuate inflammation, which
could be caused by an increase in 15(S)-HETE and
eventually by its metabolites, the lipoxins.
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Introduction
Reticulocyte-type 15-lipoxygenase-1 (ALOX15) (MIM
152392) is a lipid-peroxidizing enzyme that inserts
molecular oxygen into free and esterified polyunsat-
urated fatty acids to produce an array of bioactive lip-
ids (1). The oxidation of arachidonic acid by ALOX15
leads to 15-hydroxy-eicosatetraenoic acid (15-HETE).
This metabolite can either directly serve as a peroxi-
some proliferator-activated receptor-g (PPARg) acti-
vator (2) or be further metabolized to lipoxins, which
are involved in the resolution of inflammation (3).
Because these lipoxins were shown to inhibit che-
motaxis, adhesion and transmigration of neutrophils,
and to antagonize the pro-inflammatory effects of
leukotrienes (4), ALOX15 is thought to play an anti-
inflammatory role in the pathology of inflammatory
diseases (5).
Besides the oxidation of arachidonic acid, ALOX15
oxidizes linoleic acid to 13-hydroxy-octadecadienoic
acid (13-HODE), which is an activator of the PPARa,
PPARg and PPARd receptors (6). Intriguingly, ALOX15
can also oxidize esterified linoleic acid on low-density
lipoprotein (LDL) particles to produce the pro-athero-
genic oxidized LDL (oxLDL) (7), which has pro-inflam-
matory and immunogenic properties (8). Hence, it is
not clear whether the production of pro-atherogenic
oxLDL outweighs the anti-inflammatory effects of
ALOX15 in atherosclerosis and other inflammatory
diseases.
Because functionally relevant polymorphisms in the
ALOX15 gene could indicate whether altered ALOX15
activity does indeed influence disease progressions in
humans, we recently screened the ALOX15 gene for
polymorphisms and detected 11 variations (9, 10).
One of the polymorphisms, a C)T substitution at
position c.–292 in the ALOX15 promoter, creates a
novel binding site for the myeloid and B-cell transcrip-
tion factor SPI1 (9, 10). Binding of SPI1 to the c.–292T
promoter increased ALOX15 transcription in human
primary macrophages, but not in lung epithelial cells.
Stimulated macrophages from heterozygous c.–
292CT carriers had three-fold higher ALOX15 mRNA
levels than macrophages from homozygous c.–292CC
non-carriers (9, 10).
In this study, we investigated the influence of ele-
vated mRNA levels in c.–292CT carriers on ALOX15
enzyme activity and asked whether there is an asso-
ciation of the polymorphism with coronary artery dis-
ease (CAD). We show that the c.–292C)T promoter
polymorphism leads to an increase in ALOX15
enzyme activity upon stimulation and demonstrate
that the c.–292T allele shows a trend towards an athe-
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roprotective effect in a case-control study for CAD
involving 498 participants.
Materials and methods
Mutation analysis
DNA was extracted from EDTA blood samples using a
QIAmp DNA Mini Blood Kit (Qiagen AG, Basel, Switzerland)
and genotyping was performed according to Wittwer et al.
(9, 10).
Nomenclature
All ALOX15 numbering is based on the cDNA sequence
NM_001140.3 with the A of the ATG translation initiation
codon being taken as q1. The intronic numbers are further
based on the genomic sequence NT_010718.15. For example,
c.136-35C)T means a C)T substitution in the 35th base on
the intron upstream of the next exon starting with base num-
ber 136 according to the cDNA sequence. Sequences iden-
tical to NM_001140.3 and NT_010718.15 are called ALOX15
throughout the article.
Preparation of human peripheral blood monocytes
Lymphocytes from either c.–292CC homozygous or c.–292CT
heterozygous volunteers were extracted from 60 mL of hepa-
rinized blood using a HISTOPAQUE-1077 gradient (Sigma-
Aldrich, Buchs, Switzerland). Peripheral blood monocytes
were purified by capture on anti-CD14 antibodies coupled to
MACS MicroBeads according to the manufacturer’s instruc-
tions (CD14 Microbeads, Miltenyi Biotec, Bergisch Gladbach,
Germany). Monocytes were differentiated into macrophages
by stimulation for 3 days with 670 pM IL-4 in RPMI-1640
medium (Sigma) supplemented with 5% FCS (Fisher Scien-
tific, Wohlen, Switzerland), 5% human AB serum (Sigma)
and 5% CO2.
Enzymatic assay of ALOX15 activity
To boost IL-4 stimulation at 65 h after seeding the mono-
cytes, 670 pM IL-4 was added; 72 h after seeding, cells were
collected and counted. For each sample, 5=105 cells were
transferred to 1.5 mL of PBS, spiked with 100 mM arachido-
nic acid and incubated for 15 min at 378C. The suspension
was centrifuged and the supernatant from each sample was
stored at y208C until analysis.
HPLC analysis
15(R,S)-Hydroxy-eicosatetraenoic acid w15(R,S)-HETEx and
15(R)-HETE were purchased from Cayman Europe (Tallinn,
Estonia). n-Hexane, methanol, ethanol, 2-propanol (all HPLC
grade) were from Carl Roth (Karlsruhe, Germany). Acetic
acid and ethyl acetate were from Gru¨ssing (Filsum, Germa-
ny). The equipment consisted of a Waters 510 HPLC pump
(Vienna, Austria), a 7725i Rheodyne injector (Riemerling,
Germany) with a 20-mL sample loop, a column protection
SecurityGuard cartridge (silica; 4 mm=3 mm ID) from Phe-
nomenex (Aschaffenburg, Germany) and a Merck Hitachi L-
4500A diode-array detector (Darmstadt, Germany). Data
were analyzed using D-6500 DAD system manager software
from Hitachi (Hamburg, Germany). All chromatographic runs
were monitored at a wavelength of 235 nm (conjugated
diene system) and measurements of the absorption maxi-
mum (lmax) were performed after the run was completed.
HPLC sample preparation
Samples were extracted twice with 1.5 mL of ethyl acetate.
The combined organic layers were vaporized under a nitro-
gen stream. The residue was redissolved in 60 mL of n-hex-
ane and subjected to normal-phase HPLC.
Normal-phase HPLC
A LiChrospher Si 60 column with pure silica gel as the sta-
tionary phase from Merck (250 mm=4 mm ID, particle size
5 mm) was used. The column was eluted with n-hexane/2-
propanol/acetic acid (100:2:0.1 by vol.) at a flow rate of 1
mL/min. The 15-HETE fractions were collected and the sol-
vent was evaporated under a nitrogen stream. The residue
was redissolved in 25 mL of n-hexane and subjected to enan-
tioselective HPLC.
Enantioselective HPLC
A Chiralpak AD column of amylose Tris-(3,5-dimethylphe-
nylcarbamate) coated on silica gel from Chiral Technologies
Europe (Illkrich, France; 250 mm=4.6 mm ID, particle size
10 mm) was used. The column was eluted with n-hexane/
ethanol/methanol/acetic acid (93:4:3:0.1, by vol.) at a flow
rate of 1 mL/min.
Case-control study
A total of 342 men and 156 women from Zurich volunteered
to participate in the study (11, 12). Written informed consent
was obtained from all participants and the local Ethics Com-
mittees approved the study. The case group consisted of 260
consecutive Caucasian patients with angiographically docu-
mented CAD with more than 50% stenosis in at least one
coronary artery. The control group consisted of 238 Cauca-
sians with no history of CAD, stroke, or peripheral vascular
disease and was recruited from the general population.
Angiographically negative individuals were also included in
the control group. A cholesterol-lowering regimenwas being
followed by 81% of the cases and 8% of the controls. Risk
factors and the use of medication were assessed by ques-
tionnaire. Clinical chemistry analysis was carried out on a
Roche-Hitachi Modular Clinical Chemistry analyzer using
commercial tests from Roche Diagnostics (Rotkreuz,
Switzerland).
Statistical analyses
Statistical analysis was performed using StatView 5.0.1 and
SAS 9.1.3. (SAS Institute, Heidelberg, Germany). Continuous
variables between cases and controls were compared using
a two-sided t-test. Association of ALOX15 polymorphisms
with CAD was assessed by exact logistic regression, using
an additive genetic model and adjusting for age and sex.
Differences in C-reactive protein (CRP) levels between carri-
ers and non-carriers of the c.–292T allele were assessed by
Mann-Whitney test.
The peak areas for 15-HETE and the S/R-enantiomeric
ratios were compared by ANOVA using Scheffe’s F-test
between c.–292CC homozygous and c.–292CT heterozygous
volunteers. All p-values are two-sided, with p-0.05 consid-
ered statistically significant.
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Figure 2 Increased 15-HETE levels in supernatants from
c.–292CT heterozygous macrophages.
The areas of 15-HETE peaks in supernatants from c.–292CC
and c.–292CT macrophages were determined. Five 15-HETE
determinations were performed for c.–292CC and four for
c.–292CT genotypes. Error bars indicate the standard
deviation. The asterisk indicates a significant difference
(p-0.0001).
Figure 1 15-HETE detection in supernatant from macro-
phages.
Extracts of the supernatant of c.–292CC homozygous and
c.–292CT heterozygous macrophages following the activity
assays were loaded on a normal-phase HPLC non-chiral
LiChrospher Si 60 column and the elution profile was fol-
lowed at a wavelength of 235 nm. The retention time for 15-
HETE (7.95 min) was identified using a 15-HETE reference
standard. The arrow depicts the 15-HETE peak. The chemical
structure of 15-HETE is indicated. Other peaks were not
identified.
Results
The c.–292C)T polymorphism is functional and
increases ALOX15 activity
To investigate whether an increase in ALOX15 mRNA
would lead to higher enzyme activity, we measured
the product 15-HETE from isolated primary macro-
phages from individuals with different c.–292 geno-
types. Owing to a lack of c.–292TT homozygous
volunteers (0.2% of the population), we used mono-
cytes from c.–292CT heterozygous and c.–292CC
homozygous volunteers. Primary blood monocytes
were extracted from whole blood and IL-4 was used
to stimulate differentiation into macrophages and
expression of ALOX15 before stimulation with ar-
achidonic acid. This stimulation led to a significant
release of the ALOX15-mediated arachidonic acid
metabolite 15-HETE into the extracellular solution by
macrophages of both genotypes (Figure 1). However,
four-fold higher 15-HETE levels were observed in
supernatants from c.–292CT heterozygous macro-
phages (p-0.0001) compared to c.–292CC homozy-
gous macrophages (Figure 2).
Since arachidonic acid can undergo spontaneous
oxidation by oxygen radicals, it is essential to distin-
guish ALOX15 enzyme activity from spontaneous oxi-
dation. The product of spontaneous oxidation is a
racemic mixture of 15(R)-HETE and 15(S)-HETE, while
ALOX15 oxidizes arachidonic acid specifically to
15(S)-HETE. To assess ALOX15 activity, we separated
the 15-HETE fractions collected into their enantiomers
using enantioselective HPLC (Figure 3). Macrophages
from c.–292CT heterozygous volunteers produced
more 15(S)-HETE compared to those from c.–292CC
homozygous volunteers (Figure 3A). The average
15(S)-HETE/15(R)-HETE enantiomer ratio was 1.6 in
c.–292CC homozygous volunteers and 9.6 in c.–292CT
heterozygous volunteers (p-0.0001) (Figure 3B).
Association study of ALOX15 genetic variants with
CAD
To investigate the influence of this ALOX15 polymor-
phism on atherosclerosis, we investigated the asso-
ciation of all ALOX15 mutations and polymorphisms
with CAD in a case-control study including 260 Cau-
casian CAD cases and 238 healthy controls (12). The
characteristics of the controls and cases are shown in
Table 1. No significant correlation between genetic
variants detected in the ALOX15 gene and CAD was
observed (Table 2). However, the c.–292C)T poly-
morphism showed a trend toward association with
CAD (odds ratio 0.45, confidence interval 0.16–1.17).
Intriguingly, the c.–292T allele was more frequent in
controls (4.6%) than in cases (2.7%), suggesting that
ALOX15 could be atheroprotective in humans.
To investigate whether this atheroprotective effect
of the c.–292T allele could be explained by the anti-
inflammatory action of ALOX15, we compared CRP
levels between carriers and non-carriers of the
c.–292T allele in controls. There was no difference in
CRP levels between carriers and non-carriers w2.4
(0.8–3.8) vs. 1.3 (0.6–2.6) mg/L, median (interquartile
range); ps0.3x.
Discussion
Previously, we screened the ALOX15 gene for varia-
tions and found a c.–292C)T polymorphism in the
ALOX15 promoter that leads to higher ALOX15 mRNA
levels in primary macrophages from heterozygous
carriers through the formation of a novel binding site
for the transcription factor SPI1 (9, 10). In this study,
we demonstrate that this higher ALOX15 mRNA level
leads to higher enzyme activity and that the same
polymorphism shows a trend towards an atheropro-
tective effect in a CAD case-control study.
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Figure 3 Increased 15(S)-HETE levels result from increased ALOX15 activity in c.–292T allele carriers.
15-HETE eluted from the non-chiral HPLC column was separated into S- and R-enantiomers on a chiral HPLC column.
(A) Chromatograms of the separation of 15-HETE S- and R-enantiomers on the chiral column: (I) supernatant from c.–292CC
homozygous macrophages with an S/R-enantiomeric ratio of 1.1; (II) supernatant from c.–292CT heterozygous macrophages
with an S/R-enantiomeric ratio of 10. Retention times for the R-enantiomer (7.5 min) and S-enantiomer (9.5min) were identified
by comparison with 15-HETE reference standards. (B) Average S/R-enantiomeric ratios for 15-HETE in supernatants from
macrophages of five c.–292CC homozygous and four c.–292CT heterozygous carriers. Error bars indicate the standard devi-
ation. The asterisk indicates a significant difference (p-0.0001).
Table 2 Exact logistic regression models predicting CAD status for cases.
Variation Genotype, % Odds ratio 95% CI p-Value
Controls (ns238) Cases (ns260)
c.–635A)G 48.5/43.9/7.5 53.3/40.2/6.5 0.82 0.61–1.11 0.16
c.–511A)G 97.1/2.9/0.0 98.1/1.9/0.0 0.65 0.18–2.24 0.46
c.–292C)T 95.4/4.2/0.4 97.3/2.7/0.0 0.45 0.16–1.17 0.084
c.–272G)T 64.4/30.1/5.4 60.9/34.5/4.6 1.11 0.81–1.52 0.55
c.–186G)C 66.1/29.7/4.2 61.3/34.1/4.6 1.24 0.90–1.72 0.18
c.136-35C)T 100/0.0/0.0 98.8/1.2/0.0 3.07a 0.45–` 0.16
c.337q8C)T 51.9/41.4/6.7 57.1/36.0/6.9 0.96 0.71–1.30 0.79
c.543-16C)T 97.5/2.5/0.0 96.9/3.1/0.0 1.14 0.35–3.86 0.89
c.1564C)T 100/0.0/0.0 99.6/0.4/0.0 0.35a 0.02–` 0.63
c.1849C)T 98.7/1.3/0.0 99.6/0.4/0.0 0.52 0.02–5.35 0.82
c.2076q200C)T 65.7/30.5/3.8 68.2/28.7/3.1 0.87 0.62–1.22 0.41
aUnbiased median value.
Table 1 Characteristics of controls and cases.
Controls (ns238) Cases (ns260) p-Value
Age, years 59 (53–66) 64 (57–71) -0.0001
Male, % 58.2 78.9 -0.0001
History of hypertension, % 28.9 46.7 -0.0001
History of diabetes, % 3.6 20.7 -0.0001
History of high cholesterol, % 19.7 51.3 -0.0001
Smoking, % 47.4 73.6 -0.0001
Body mass index, kg/m2 25.7 (23.0–28.4) 26.8 (24.5–29.8) -0.0001
Creatinine, mmol/L 90 (83–99) 89 (80–99) 0.14
CRP, mg/L 2 (1–3) 2 (1–4) -0.0001
Cholesterol, mmol/L 5.9 (5.1–6.5) 5.1 (4.4–5.9) -0.0001
HDL, mmol/L 1.6 (1.3–2.0) 1.3 (1.1–1.4) -0.0001
LDL, mmol/L 3.5 (2.8–4.0) 3.2 (2.5–3.9) 0.0096
Triglycerides, mmol/L 1.4 (0.9–2.0) 1.3 (1.0–1.8) 0.79
Results are presented as median (interquartile range) or percentage.
ALOX15 directly catalyzes formation of the arachi-
donic acid metabolite 15(S)-HETE, which is an endo-
genous inhibitor of inflammation. For example,
15(S)-HETE directly inhibits 5-LOX and superoxide
production (13), and inhibits polymorphonuclear neu-
trophil (PMN) degranulation following stimulation
with leukotriene B4 (14). 15(S)-HETE production also
inhibits PMN migration across cytokine-activated
endothelium in vitro (15). This inhibition of migration
is further assisted by the metabolism of 15(S)-HETE
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into its derivatives lipoxin A4 and B4. The lipoxins
have also been shown to antagonize the pro-inflam-
matory effects of leukotrienes, reduce neutrophil che-
motaxis and block neutrophil entry across the in-
testinal epithelium and to be involved in the resolu-
tion of inflammation (16).
This anti-inflammatory effect may play a role in ath-
erosclerosis, since the c.–292C)T polymorphism
showed a trend towards an atheroprotective effect in
a human CAD case-control study. In this study, the
c.–292T allele was less frequent in patients with CAD
(2.7%) compared to controls (4.6%), and carriers of
the c.-292T allele showed a non-significant reduction
in risk for atherosclerosis (odds ratio 0.45, confidence
interval 0.16–1.17). These results are in line with
the atheroprotective role of the monocyte-specific
ALOX15 expression in transgenic rabbits (17, 18),
which produced higher levels of the anti-inflamma-
tory factor lipoxin A4 (19). This led to an over-
all enhancement of endogenous anti-inflammation,
which resulted in a lower degree of atherosclerosis
upon feeding of a cholesterol-rich diet (19). However,
not all animal models showed an atheroprotective
role of ALOX15. In apoE–/– mice, conditional macro-
phage-specific and general disruption of the ALOX15
homologue gene 12(S)/15(S)-LOX reduced atheroscle-
rosis (20, 21). In line with the pro-atherogenic effect
of ALOX15 in mice, endothelial overexpression of
human ALOX15 enhanced atherosclerosis (22). This
discrepancy in the function of ALOX15 between dif-
ferent species can be explained by the finding that
each animal has a different set of 12-LOX and 15-
LOX isoenzymes with different enzymatic properties.
When these enzymes are knocked out or overexpress-
ed in different animals and cells, this can cause diver-
gent effects. In this context, higher expression of
ALOX15 in human macrophages seems to be athero-
protective, as in transgenic rabbits that overexpress
reticulocyte-type 15(S)-LOX (17, 18).
Although our results indicate a trend towards an
atheroprotective effect for the c.–292T allele, there
was no significant association, which may be due to
the low allele frequency (2.5%) of the mutant c.–292T
allele in the study population (9, 10) and the small
sample size. Our sample with 498 participants is too
small to detect a significant association with enough
power. The sample size necessary to detect an odds
ratio of 0.5 with statistical power of 80% and a c.–292T
allele carrier frequency of 4.6% is 1170 subjects.
Hence, larger studies to analyze the association of this
polymorphism with CAD are required to investigate
whether increased ALOX15 expression and activity
in the physiological range is anti-atherogenic in
humans.
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